Researchers at University of California San Diego School of Medicine identified new therapeutic targets for gastrointestinal stromal tumors (GISTs) that could lead to new treatment options for patients.
UC San Diego researchers report that individual immune response to SARS-CoV-2 may be limited by a set of variable genes that code for cell surface proteins essential for the adaptive immune system. The finding may help explain why COVID-19 immunity varies by individual.
The Department of Surgery announces four new division chair appointments, effective immediately. The organizational changes will advance state-of-the-art technologies, drive innovative surgical techniques to improve patient outcomes, and foster translational and patient centered research.
No patients admitted to the UC Davis Medical Center tested positive for the flu this entire season, and experts credit flu vaccines, masking and social distancing with averting a possible “twindemic” of influenza and COVID-19.
UC San Diego researchers will inject harmless virus carrying a restorative gene into participants’ brains, where earlier animal studies suggest it may slow, prevent or reverse progression of the neurological disorder
Gastrointestinal stromal tumors (GISTs) are a subtype of cancers known as sarcomas. GIST is the most common type of sarcoma with approximately 5,000 to 6,000 new patient cases annually in the United States. GIST cannot be cured by drugs alone, and targeted therapies are only modestly effective,...
The UC Davis Children’s Hospital Transport Team specializes in bringing an advanced level of care to infants and children at surrounding community hospitals, where appropriate resources may not be available.
Computational studies suggest a set of genes that regulate immune response help determine robustness and durability of neutralizing antibodies to virus
Health Media Contacts
Find the best contact for health-related media inquiries.
